Search

Your search keyword '"Tola, M.R."' showing total 27 results
Start Over Author "Tola, M.R."
27 results on '"Tola, M.R."'

1. The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power

Author

Baruzzi, A., Albani, F., Calbucci, F., D'Alessandro, R., Michelucci, R., Brandes, A., Eusebi, V., Ceruti, S., Fainardi, E., Tamarozzi, R., Emiliani, E., Cavallo, M., Franceschi, E., Tosoni, A., Fiorica, F., Valentini, A., Depenni, R., Mucciarini, C., Crisi, G., Sasso, E., Biasini, C., Cavanna, L., Guidetti, D., Marcello, N., Pisanello, A., Cremonini, A.M., Guiducci, G., de Pasqua, S., Testoni, S., Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, S., Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Crisci, M., Dall'Occa, P., de Biase, D., Ferro, S., Franceschi, C., Frezza, G., Grasso, V., Leonardi, M., Marucci, G., Morandi, L., Mostacci, B., Palandri, G., Pasini, E., Pastore Trossello, M., Pession, A., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., Trocino, C., Dall'Agata, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A., Strumia, S., Faedi, M., Casmiro, M., Gamboni, A., Rasi, F., Cruciani, G., Cenni, P., Dazzi, C., Guidi, A.R., Zumaglini, F., Amadori, A., Pasini, G., Pasquinelli, M., Pasquini, E., Polselli, A., Ravasio, A., Viti, B., Sintini, M., Ariatti, A., Bertolini, F., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, S., Nichelli, P., Pettorelli, E., Pinna, G., Zunarelli, E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., Stucchi, C., Iaccarino, C., Ragazzi, M., Rizzi, R., Zuccoli, G., Api, P., Cartei, F., Colella, M., Fallica, E., Farneti, M., Frassoldati, A., Granieri, E., Latini, F., Monetti, C., Saletti, A., Schivalocchi, R., Sarubbo, S., Seraceni, S., Tola, M.R., Urbini, B., Zini, G., Giorgi, C., Montanari, E., Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Servadei, F., Silini, E.M., Torelli, P., Immovilli, P., Morelli, N., Vanzo, C., Nobile, C., Franceschi, Enrico, Tosoni, Alicia, Minichillo, Santino, Depenni, Roberta, Paccapelo, Alexandro, Bartolini, Stefania, Michiara, Maria, Pavesi, Giacomo, Urbini, Benedetta, Crisi, Girolamo, Cavallo, Michele A., Tosatto, Luigino, Dazzi, Claudio, Biasini, Claudia, Pasini, Giuseppe, Balestrini, Damiano, Zanelli, Francesca, Ramponi, Vania, Fioravanti, Antonio, Giombelli, Ermanno, De Biase, Dario, Baruzzi, Agostino, and Brandes, Alba A.

Published
2018
Full Text
View/download PDF

4. The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power

Author

Franceschi, Enrico, primary, Tosoni, Alicia, additional, Minichillo, Santino, additional, Depenni, Roberta, additional, Paccapelo, Alexandro, additional, Bartolini, Stefania, additional, Michiara, Maria, additional, Pavesi, Giacomo, additional, Urbini, Benedetta, additional, Crisi, Girolamo, additional, Cavallo, Michele A., additional, Tosatto, Luigino, additional, Dazzi, Claudio, additional, Biasini, Claudia, additional, Pasini, Giuseppe, additional, Balestrini, Damiano, additional, Zanelli, Francesca, additional, Ramponi, Vania, additional, Fioravanti, Antonio, additional, Giombelli, Ermanno, additional, De Biase, Dario, additional, Baruzzi, Agostino, additional, Brandes, Alba A., additional, Baruzzi, A., additional, Albani, F., additional, Calbucci, F., additional, D'Alessandro, R., additional, Michelucci, R., additional, Brandes, A., additional, Eusebi, V., additional, Ceruti, S., additional, Fainardi, E., additional, Tamarozzi, R., additional, Emiliani, E., additional, Cavallo, M., additional, Franceschi, E., additional, Tosoni, A., additional, Fiorica, F., additional, Valentini, A., additional, Depenni, R., additional, Mucciarini, C., additional, Crisi, G., additional, Sasso, E., additional, Biasini, C., additional, Cavanna, L., additional, Guidetti, D., additional, Marcello, N., additional, Pisanello, A., additional, Cremonini, A.M., additional, Guiducci, G., additional, de Pasqua, S., additional, Testoni, S., additional, Agati, R., additional, Ambrosetto, G., additional, Bacci, A., additional, Baldin, E., additional, Baldrati, A., additional, Barbieri, E., additional, Bartolini, S., additional, Bellavista, E., additional, Bisulli, F., additional, Bonora, E., additional, Bunkheila, F., additional, Carelli, V., additional, Crisci, M., additional, Dall'Occa, P., additional, de Biase, D., additional, Ferro, S., additional, Franceschi, C., additional, Frezza, G., additional, Grasso, V., additional, Leonardi, M., additional, Marucci, G., additional, Morandi, L., additional, Mostacci, B., additional, Palandri, G., additional, Pasini, E., additional, Pastore Trossello, M., additional, Pession, A., additional, Poggi, R., additional, Riguzzi, P., additional, Rinaldi, R., additional, Rizzi, S., additional, Romeo, G., additional, Spagnolli, F., additional, Tinuper, P., additional, Trocino, C., additional, Dall'Agata, M., additional, Frattarelli, M., additional, Gentili, G., additional, Giovannini, A., additional, Iorio, P., additional, Pasquini, U., additional, Galletti, G., additional, Guidi, C., additional, Neri, W., additional, Patuelli, A., additional, Strumia, S., additional, Faedi, M., additional, Casmiro, M., additional, Gamboni, A., additional, Rasi, F., additional, Cruciani, G., additional, Cenni, P., additional, Dazzi, C., additional, Guidi, A.R., additional, Zumaglini, F., additional, Amadori, A., additional, Pasini, G., additional, Pasquinelli, M., additional, Pasquini, E., additional, Polselli, A., additional, Ravasio, A., additional, Viti, B., additional, Sintini, M., additional, Ariatti, A., additional, Bertolini, F., additional, Bigliardi, G., additional, Carpeggiani, P., additional, Cavalleri, F., additional, Meletti, S., additional, Nichelli, P., additional, Pettorelli, E., additional, Pinna, G., additional, Zunarelli, E., additional, Artioli, F., additional, Bernardini, I., additional, Costa, M., additional, Greco, G., additional, Guerzoni, R., additional, Stucchi, C., additional, Iaccarino, C., additional, Ragazzi, M., additional, Rizzi, R., additional, Zuccoli, G., additional, Api, P., additional, Cartei, F., additional, Colella, M., additional, Fallica, E., additional, Farneti, M., additional, Frassoldati, A., additional, Granieri, E., additional, Latini, F., additional, Monetti, C., additional, Saletti, A., additional, Schivalocchi, R., additional, Sarubbo, S., additional, Seraceni, S., additional, Tola, M.R., additional, Urbini, B., additional, Zini, G., additional, Giorgi, C., additional, Montanari, E., additional, Cerasti, D., additional, Crafa, P., additional, Dascola, I., additional, Florindo, I., additional, Giombelli, E., additional, Mazza, S., additional, Ramponi, V., additional, Servadei, F., additional, Silini, E.M., additional, Torelli, P., additional, Immovilli, P., additional, Morelli, N., additional, Vanzo, C., additional, and Nobile, C., additional

Published
2018
Full Text
View/download PDF

5. Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS

Author

Lavie, Caroline, primary, Rollot, Fabien, additional, Durand-Dubief, Françoise, additional, Marignier, Romain, additional, Ionescu, Iuliana, additional, Casey, Romain, additional, Moreau, Thibault, additional, Tourniaire, Patricia, additional, Hutchinson, Michael, additional, D’Hooghe, Marie Béatrice, additional, Laplaud, David-Axel, additional, Clavelou, Pierre, additional, De Sèze, Jérôme, additional, Debouverie, Marc, additional, Brassat, David, additional, Pelletier, Jean, additional, Lebrun-Frenay, Christine, additional, Le Page, Emmanuelle, additional, Castelnovo, Giovanni, additional, Berger, Eric, additional, Hautecoeur, Patrick, additional, Heinzlef, Olivier, additional, Durelli, Luca, additional, Clerico, Marinella, additional, Trojano, Maria, additional, Patti, Francesco, additional, Vukusic, Sandra, additional, Alpérovitch, A., additional, Carton, H., additional, d’Hooghe, M.B., additional, Hommes, O., additional, Hutchinson, M., additional, Adeleine, P., additional, Biron, A., additional, Cortinovis-Tourniaire, P., additional, Grimaud, J., additional, Hours, M., additional, Moreau, T., additional, Vukusic, S., additional, Confavreux, C., additional, Chauplannaz, G., additional, Latombe, D., additional, Clanet, M., additional, Lau, G., additional, Rumbach, L., additional, Goas, J.Y., additional, Rouhart, F., additional, Mazingue, A., additional, Roullet, E., additional, Madigand, M., additional, Hautecoeur, P., additional, Brunet, P., additional, Edan, G., additional, Allaire, C., additional, Riffault, G., additional, Leche, J., additional, Benoit, T., additional, Simonin, C., additional, Ziegler, F., additional, Baron, J.C., additional, Rivrain, Y., additional, Dumas, R., additional, Loche, D., additional, Bourrin, J.C., additional, Huttin, B., additional, Delisse, B., additional, Gibert, I., additional, Boulay, C., additional, Verceletto, M., additional, Durand, G., additional, Bonneviot, G., additional, Gil, R., additional, Hedreville, M.A., additional, Belair, C., additional, Poitevin, R.J., additional, Devoize, J.L., additional, Wyremblewski, P., additional, Delestre, F., additional, Setiey, A., additional, Comi, G., additional, Filippi, M., additional, Ghezzi, A., additional, Martinelli, V., additional, Rossi, P., additional, Zaffaroni, M., additional, Tola, M.R., additional, Amato, M.P., additional, Fioretti, C., additional, Meucci, G., additional, Inglese, M., additional, Mancardi, G.L., additional, Gambi, D., additional, Thomas, A., additional, Cavazzuti, M., additional, Citterio, A., additional, Heltberg, A., additional, Hansen, H.J., additional, Fernandez, O., additional, Romero, F., additional, Arbizu, T., additional, Hernandez, J.J., additional, De Andres de Frutos, C., additional, Geffner Sclarky, D., additional, Aladro Benito, Y., additional, Reyes Yanes, P., additional, Aguilar, M, additional, Burguera, J.A., additional, Yaya, R., additional, Bonakim Dib, W., additional, Arzua-Mouronte, D., additional, Sindic, C.J.M., additional, Medaer, R., additional, Roose, H., additional, Geens, K.M.J., additional, Guillaume, D., additional, Van Zandycke, M., additional, Janssens, J., additional, Cornette, M., additional, Mol, L., additional, Weilbach, F., additional, Flachenecker, P., additional, Hartung, H.P., additional, Haas, J., additional, Tendolkar, I., additional, Sindrn, E., additional, Kölmel, H.W., additional, Reichel, D., additional, Rauch, M., additional, Preuss, S., additional, Poser, S., additional, Mauch, E., additional, Strausser-Fuchs, S., additional, Kolleger, H., additional, Hawkins, S., additional, Howell, S.J.L., additional, Rees, J.E., additional, Thompson, A., additional, Johnson, M., additional, Boggild, M., additional, Gregory, R.P., additional, Bates, D., additional, Bone, I., additional, Polman, C., additional, Frequin, S., additional, Jongen, P., additional, Correia de Sa, J., additional, Rio, M.E., additional, Huber, S., additional, Lechner-Scott, J., additional, Kappos, L., additional, Ionescu, I., additional, Cornu, C., additional, El-Etr, M., additional, Baulieu, E.E., additional, Schumacher, M, additional, Miller, D.H., additional, Pugeat, M., additional, d’Archangues, C., additional, Conard, J., additional, Ménard, J., additional, Sitruk-Ware, R., additional, Pelissier, C., additional, Dat, S., additional, Belaïsch-Allard, J., additional, Athéa, N., additional, Büschsenschutz, D., additional, Lyon-Caen, O., additional, Gonsette, R., additional, Boissel, J.P., additional, Ffrench, P., additional, Durand-Dubief, F., additional, Cotton, F., additional, Pachai, C., additional, Bracoud, L., additional, Androdias, G., additional, Marignier, R., additional, Laplaud, D.A., additional, Wiertlewski, S., additional, Lanctin-Garcia, C., additional, Couvreur, G., additional, Madinier, G., additional, Clavelou, P., additional, Taithe, F., additional, Aufauvre, D., additional, Guy, N., additional, Ferrier, A., additional, De Sèze, J., additional, Collongues, N., additional, Debouverie, M., additional, Viala, F., additional, Brassat, D., additional, Gerdelat-Mas, A., additional, Henry, P., additional, Pelletier, J., additional, Rico-Lamy, A., additional, Lebrun-Frenay, C., additional, Lepage, E., additional, Deburghraeve, V., additional, Castelnovo, G., additional, Berger, E., additional, Blondiau, M., additional, Heinzlef, O., additional, Coustans, M., additional, Clerc, C., additional, Rieu, L., additional, Lauxerois, M., additional, Hinzelin, G., additional, Ouallet, J.C., additional, Minier, D., additional, Vion, P., additional, Gromaire-Fayolle, N., additional, Derache, N., additional, Thouvenot, E., additional, Sallansonnet-Froment, M., additional, Tourniaire, P., additional, Toureille, L., additional, Borgel, F., additional, Stankoff, B., additional, Moroianu, C., additional, Guennoc, A.M., additional, Tournier-Gervason, C.L., additional, Peysson, S., additional, Trojano, M., additional, Patti, F., additional, D’Amico, E., additional, Motti, L., additional, Durelli, L., additional, and Tavella, A., additional

Published
2018
Full Text
View/download PDF

7. Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?

Author

Brandes, Alba A., primary, Franceschi, Enrico, additional, Ermani, Mario, additional, Tosoni, Alicia, additional, Albani, Fiorenzo, additional, Depenni, Roberta, additional, Faedi, Marina, additional, Pisanello, Anna, additional, Crisi, Girolamo, additional, Urbini, Benedetta, additional, Dazzi, Claudio, additional, Cavanna, Luigi, additional, Mucciarini, Claudia, additional, Pasini, Giuseppe, additional, Bartolini, Stefania, additional, Marucci, Gianluca, additional, Morandi, Luca, additional, Zunarelli, Elena, additional, Cerasoli, Serenella, additional, Gardini, Giorgio, additional, Lanza, Giovanni, additional, Silini, Enrico Maria, additional, Cavuto, Silvio, additional, Baruzzi, Agostino, additional, Baruzzi, A., additional, Albani, F., additional, Calbucci, F., additional, D'Alessandro, R., additional, Michelucci, R., additional, Brandes, A., additional, Eusebi, V., additional, Ceruti, S., additional, Fainardi, E., additional, Tamarozzi, R., additional, Emiliani, E., additional, Cavallo, M., additional, Franceschi, E., additional, Tosoni, A., additional, Fiorica, F., additional, Valentini, A., additional, Depenni, R., additional, Mucciarini, C., additional, Crisi, G., additional, Sasso, E., additional, Biasini, C., additional, Cavanna, L., additional, Guidetti, D., additional, Marcello, N., additional, Pisanello, A., additional, Cremonini, A.M., additional, Guiducci, G., additional, de Pasqua, S., additional, Testoni, S., additional, Agati, R., additional, Ambrosetto, G., additional, Bacci, A., additional, Baldin, E., additional, Baldrati, A., additional, Barbieri, E., additional, Bartolini, S., additional, Bellavista, E., additional, Bisulli, F., additional, Bonora, E., additional, Bunkheila, F., additional, Carelli, V., additional, Crisci, M., additional, Dall'Occa, P., additional, de Biase, D., additional, Ferro, S., additional, Franceschi, C., additional, Frezza, G., additional, Grasso, V., additional, Leonardi, M., additional, Marucci, G., additional, Mazzocchi, V., additional, Morandi, L., additional, Mostacci, B., additional, Palandri, G., additional, Pasini, E., additional, Pastore Trossello, M., additional, Pession, A., additional, Ragazzi, M., additional, Riguzzi, P., additional, Rinaldi, R., additional, Rizzi, S., additional, Romeo, G., additional, Spagnolli, F., additional, Tinuper, P., additional, Trocino, C., additional, Cerasoli, S., additional, Dall'Agata, M., additional, Faedi, M., additional, Frattarelli, M., additional, Gentili, G., additional, Giovannini, A., additional, Iorio, P., additional, Pasquini, U., additional, Galletti, G., additional, Guidi, C., additional, Neri, W., additional, Patuelli, A., additional, Strumia, S., additional, Casmiro, M., additional, Gamboni, A., additional, Rasi, F., additional, Cruciani, G., additional, Cenni, P., additional, Dazzi, C., additional, Guidi, AR., additional, Zumaglini, F., additional, Amadori, A., additional, Pasini, G., additional, Pasquinelli, M., additional, Pasquini, E., additional, Polselli, A., additional, Ravasio, A., additional, Viti, B., additional, Sintini, M., additional, Ariatti, A., additional, Bertolini, F., additional, Bigliardi, G., additional, Carpeggiani, P., additional, Cavalleri, F., additional, Meletti, S., additional, Nichelli, P., additional, Pettorelli, E., additional, Pinna, G., additional, Zunarelli, E., additional, Artioli, F., additional, Bernardini, I., additional, Costa, M., additional, Greco, G., additional, Guerzoni, R., additional, Stucchi, C., additional, Iaccarino, C., additional, Rizzi, R., additional, Zuccoli, G., additional, Api, P., additional, Cartei, F., additional, Fallica, E., additional, Granieri, E., additional, Latini, F., additional, Lelli, G., additional, Monetti, C., additional, Ramponi, V., additional, Saletti, A., additional, Schivalocchi, R., additional, Seraceni, S., additional, Tola, M.R., additional, Urbini, B., additional, Giorgi, C., additional, Montanari, E., additional, Cerasti, D., additional, Crafa, P., additional, Dascola, I., additional, Florindo, I., additional, Mazza, S., additional, Servadei, F., additional, Silini, EM., additional, Torelli, P., additional, Immovilli, P., additional, Morelli, N., additional, and Vanzo, C., additional

Published
2014
Full Text
View/download PDF

10. Lithium carbonate in amyotrophic lateral sclerosis

Author

Chiò, A., primary, Borghero, G., additional, Calvo, A., additional, Capasso, M., additional, Caponnetto, C., additional, Corbo, M., additional, Giannini, F., additional, Logroscino, G., additional, Mandrioli, J., additional, Marcello, N., additional, Mazzini, L., additional, Moglia, C., additional, Monsurrò, M.R., additional, Mora, G., additional, Patti, F., additional, Perini, M., additional, Pietrini, V., additional, Pisano, F., additional, Pupillo, E., additional, Sabatelli, M., additional, Salvi, F., additional, Silani, V., additional, Simone, I.L., additional, Sorarù, G., additional, Tola, M.R., additional, Volanti, P., additional, and Beghi, E., additional

Published
2010
Full Text
View/download PDF

15. Quantitative electroencephalography: a limit towards the development of a multicenter database?

Author

Battistini, N., primary, Cianchetti, C., additional, Comi, G., additional, Onofrj, M., additional, Mancia, D., additional, Massetani, R., additional, Pinto, F., additional, Primavera, A., additional, Rocchi, R., additional, Rossini, P.M., additional, Sannita, W., additional, Signorini, M., additional, Tola, M.R., additional, and Zappoli, R., additional

Published
1996
Full Text
View/download PDF

17. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.

Author

Patti, F., Amato, M.P, Trojano, M., Bastianello, S., Tola, M.R., Goretti, B., Caniatti, L., Monte, E. Di, Ferrazza, P., Morra, V. Brescia, Lo Fermo, S., Picconi, O., and Luccichenti, G.

Subjects
COGNITION disorders, MULTIPLE sclerosis, MEDICAL imaging systems, VIRUS diseases, MAGNETIC resonance imaging, INTELLIGENCE levels
Abstract

Background Cognitive impairment is a common symptom of multiple sclerosis (MS), but the association between cognitive impairment and magnetic resonance imaging (MRI) disease measures in patients with relapsing-remitting (RR) MS is unclear. Objectives To study the prevalence of cognitive impairment and its relation with MRI disease measures in mildly disabled patients with RRMS. Methods Patients aged 18-50 years with RRMS (McDonald criteria) and an Expanded Disability Status Scale (EDSS) score ⩽4.0, who were enrolled in the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study, underwent baseline standardized MRI complete neurological examination and neuropsychological testing. Results A total of 550 patients were enrolled, 327 of whom underwent MRI assessments. Cognitive impairment (impaired performance in =3 cognitive tests) was present in approximately 20% of all patients and in the subgroup who underwent MRI. T2 hyperintense and T1 hypointense lesion volumes were significantly higher in patients with cognitive impairment (defined as impaired performance on at least three tests of the Rao's battery) than those without. EDSS score was also significantly higher in cognitively impaired than in cognitively preserved patients. Disease duration, depression, and years in formal education did not differ significantly between cognitively impaired and cognitively preserved patients. T2 lesion volume, performance intelligence quotient, and age were significant predictors of cognitive impairment in this population.Weak correlations were found between performance on individual cognitive tests and specific MRI measures, with T1 and T2 lesion volumes correlating with performance on most cognitive tests. Conclusions Cognitive impairment occurs in approximately one-fifth of mildly disabled patients with MS and is associated with specific MRI disease measures. Assessment of cognitive function at diagnosis could facilitate the identification of patients who may benefit from therapeutic intervention with disease-modifying therapies to prevent further lesion development. [ABSTRACT FROM AUTHOR]

Published
2009

18. Breastfeeding is not related to postpartum relapses in multiple sclerosis

Author

Portaccio, E., Ghezzi, A., Hakiki, B., Martinelli, V., Moiola, L., Patti, F., La Mantia, L., Mancardi, G.L., Solaro, C., Tola, M.R., Pozzilli, C., De Giglio, L., Totaro, R., Lugaresi, A., De Luca, G., Paolicelli, D., Marrosu, M.G., Comi, G., Trojano, M., and Amato, M.P.

Abstract

To assess the relationship between breastfeeding and risk of puerperal relapses in a large cohort of patients with multiple sclerosis (MS).

Published
2011
Full Text
View/download PDF

19. Pregnancy and fetal outcomes after interferon- exposure in multiple sclerosis

Author

Amato, M.P., Portaccio, E., Ghezzi, A., Hakiki, B., Zipoli, V., Martinelli, V., Moiola, L., Patti, F., La Mantia, L., Mancardi, G.L., Solaro, C., Tola, M.R., Pozzilli, C., De Giglio, L., Totaro, R., Lugaresi, A., Di Tommaso, V., Paolicelli, D., Marrosu, M.G., Comi, G., Pellegrini, F., and Trojano, M.

Abstract

To assess pregnancy and fetal outcomes after in utero exposure to interferon- (IFN) in all pregnancies occurring in women with multiple sclerosis (MS) during the study period, with a specific focus on the risk of spontaneous abortion.

Published
2010
Full Text
View/download PDF

21. A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements

Author

Franchignoni, Franco, Mandrioli, Jessica, Giordano, Andrea, Ferro, Salvatore, Mandrioli, J., Fini, N., Georgoulopoulou, E., Nichelli, P., Biguzzi, S., Venturini, E., Passarin, M. G., Guidi, C., Neri, W., Sette, E., Tugnoli, V., Tola, M. R., Terlizzi, E., Guidetti, D., Curro Dossi, M., Pasquinelli, M., Andruccioli, J., Ravasio, A., Casmiro, M., Rasi, F., Salvi, F., Bartolomei, I., Michelucci, R., Avoni, P., De Pasqua, S., Liguori, R., Rizzi, R., Canali, E., Marcello, N., Grassi, A., Delay, L., Pietrini, V., Aiello, M., Chierici, E., Montanari, E., Santangelo, M., Amidei, S., Greco, G., Casetta, I., Groppo, E., Granieri, E., De Massis, P., Mussuto, V., Borghi, A., Gabellini, A., Sacquegna, T., Rinaldi, R., Cirignotta, F., Ferro, S., D'Alessandro, R., Franchignoni, Franco, Mandrioli, Jessica, Giordano, Andrea, Ferro, Salvatore, Mandrioli, J., Fini, N., Georgoulopoulou, E., Nichelli, P., Biguzzi, S., Venturini, E., Passarin, M.G., Guidi, C., Neri, W., Sette, E., Tugnoli, V., Tola, M.R., Terlizzi, E., Guidetti, D., Curro Dossi, M., Pasquinelli, M., Andruccioli, J., Ravasio, A., Casmiro, M., Rasi, F., Salvi, F., Bartolomei, I., Michelucci, R., Avoni, P., De Pasqua, S., Liguori, R., Rizzi, R., Canali, E., Marcello, N., Grassi, A., Delay, L., Pietrini, V., Aiello, M., Chierici, E., Montanari, E., Santangelo, M., Amidei, S., Greco, G., Casetta, I., Groppo, E., Granieri, E., De Massis, P., Mussuto, V., Borghi, A., Gabellini, A., Sacquegna, T., Rinaldi, R., Cirignotta, F., Ferro, S., and D'Alessandro, R.

Subjects
Rasch analysi, Adult, Male, medicine.medical_specialty, Psychometrics, Community Health Planning, Retrospective Studie, ALSFRS-R, medicine, Humans, Respiratory function, Amyotrophic lateral sclerosis, Amyotrophic lateral sclerosi, population based study, Aged, Retrospective Studies, Rasch model, Alsfrs r, Amyotrophic Lateral Sclerosis, Rasch analysis, Retrospective cohort study, Middle Aged, medicine.disease, Differential item functioning, Confirmatory factor analysis, Neurology, Physical therapy, Female, Neurology (clinical), Factor Analysis, Statistical, Psychology, Psychometric, Human
Abstract

Our objective was to verify and expand previous evidence of psychometric inadequacies in the ALSFRS-R, in a different sample of subjects suffering from ALS. Since 2009, a prospective registry records all incident cases of ALS in Emilia Romagna Region, Italy (4.4 million inhabitants) referred to its 17 neurological departments. For each patient, demographic and clinical information is collected by the physician in charge, including compilation of the ALSFRS-R at each clinical follow-up. Results showed that a confirmatory factor analysis on the three-factor model previously found (bulbar, motor, respiratory function) showed a good fit. Rasch analysis on the whole scale showed the need to collapse some rating categories, confirmed the multidimensionality of the ALSFRS-R, and demonstrated the presence of differential item functioning between patients with spinal versus bulbar onset. Moreover, some items included in the three ALSFRS-R subscales showed a problematic fit to the respective construct they were intended to measure. In conclusion, the interpretation of a total raw score of ALSFRS-R is hampered by ambiguities due to the different metric properties of the three domains the scale aggregates, and their content and structure. This study confirms that a refinement of ALSFRS-R is warranted, pointing to the need to revise its whole structure, and providing detailed guidelines for its revision.

Published
2015

22. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study

Author

Franceschi, Enrico, Depenni, R., Paccapelo, Alexandro, Ermani, Mario, Faedi, M., Sturiale, Carmelo, Michiara, Maria, Servadei, F., Pavesi, Giacomo, Urbini, B., Pisanello, A., Crisi, G., Cavallo, Michele A., Dazzi, C., Biasini, C., Bertolini, F., Mucciarini, C., Pasini, G., Baruzzi, Agostino, Brandes, Alba A, Albani, F., Calbucci, F., D’Alessandro, R., Michelucci, R., de Pasqua, S., Testoni, S., Brandes, A., Franceschi, E., Tosoni, A., Eusebi, V., Ceruti, S., Fainardi, E., Tamarozzi, R., Emiliani, E., Cavallo, M., Fiorica, F., Sasso, E., Cavanna, L., Guidetti, D., Marcello, N., Cremonini, A. M., Guiducci, G., Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, S., Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Crisci, M., Dall’Occa, P., de Biase, D., Ferro, S., Franceschi, C., Frezza, G., Grasso, V., Leonardi, M., Marucci, G., Morandi, L., Mostacci, B., Palandri, G., Pasini, E., Pastore Trossello, M., Pession, A., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., Trocino, C., Dall’Agata, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A., Strumia, S., Casmiro, M., Gamboni, A., Rasi, F., Cruciani, G., Cenni, P., Guidi, A. R., Zumaglini, F., Amadori, A., Pasquinelli, M., Pasquini, E., Polselli, A., Ravasio, A., Viti, B., Sintini, M., Ariatti, A., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, Stefano, Nichelli, Paolo Frigio, Pettorelli, E., Pinna, G., Zunarelli, E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., Stucchi, C., Iaccarino, C., Ragazzi, M., Rizzi, R., Zuccoli, G., Api, P., Cartei, F., Colella, M., Fallica, E., Farneti, M., Frassoldati, A., Granieri, E., Latini, F., Monetti, C., Saletti, A., Schivalocchi, R., Sarubbo, S., Seraceni, S., Tola, M. R., Zini, G., Giorgi, C., Montanari, E., Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Silini, E. M., Torelli, P., Immovilli, P., Morelli, N., Vanzo, C., Nobile, C., Franceschi, E., Depenni, R., Paccapelo, Alexandro, Ermani, Mario, Faedi, M., Sturiale, Carmelo, Michiara, Maria, Servadei, F., Pavesi, Giacomo, Urbini, B., Pisanello, A., Crisi, G., Cavallo, Michele A., Dazzi, C., Biasini, C., Bertolini, F., Mucciarini, C., Pasini, G., Baruzzi, Agostino, Brandes, Alba A., Albani, F., Calbucci, F., D’Alessandro, R., Michelucci, R., de Pasqua, S., Testoni, S., Brandes, A., Tosoni, A., Eusebi, V., Ceruti, S., Fainardi, E., Tamarozzi, R., Emiliani, E., Cavallo, M., Fiorica, F., Sasso, E., Cavanna, L., Guidetti, D., Marcello, N., Cremonini, A.M., Guiducci, G., Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, S., Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Crisci, M., Dall’Occa, P., de Biase, D., Ferro, S., Franceschi, C., Frezza, G., Grasso, V., Leonardi, M., Marucci, G., Morandi, L., Mostacci, B., Palandri, G., Pasini, E., Pastore Trossello, M., Pession, A., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., Trocino, C., Dall’Agata, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A., Strumia, S., Casmiro, M., Gamboni, A., Rasi, F., Cruciani, G., Cenni, P., Guidi, A.R., Zumaglini, F., Amadori, A., Pasquinelli, M., Pasquini, E., Polselli, A., Ravasio, A., Viti, B., Sintini, M., Ariatti, A., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, S., Nichelli, P., Pettorelli, E., Pinna, G., Zunarelli, E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., Stucchi, C., Iaccarino, C., Ragazzi, M., Rizzi, R., Zuccoli, G., Api, P., Cartei, F., Colella, M., Fallica, E., Farneti, M., Frassoldati, A., Granieri, E., Latini, F., Monetti, C., Saletti, A., Schivalocchi, R., Sarubbo, S., Seraceni, S., Tola, M.R., Zini, G., Giorgi, C., Montanari, E., Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Silini, E.M., Torelli, P., Immovilli, P., Morelli, N., Vanzo, C., and Nobile, C.

Subjects
Oncology, medicine.medical_specialty, Cancer Research, medicine.medical_treatment, Dacarbazine, Population, Context (language use), NO, 03 medical and health sciences, 0302 clinical medicine, Elderly, Internal medicine, medicine, Temozolomide, Humans, MGMT methylation, Prospective Studies, Prospective cohort study, education, Promoter Regions, Genetic, Antineoplastic Agents, Alkylating, DNA Modification Methylases, Survival analysis, Aged, Aged, 80 and over, education.field_of_study, Radiotherapy, business.industry, Brain Neoplasms, Tumor Suppressor Proteins, Glioblastoma, Neurology (clinical), Neurology, DNA Methylation, Survival Analysis, Surgery, Radiation therapy, DNA Repair Enzymes, 030220 oncology & carcinogenesis, Concomitant, business, 030217 neurology & neurosurgery, medicine.drug
Abstract

The role of temozolomide concurrent with and adjuvant to radiotherapy (RT/TMZ) in elderly patients with glioblastoma (GBM) remains unclear. We evaluated the outcome of patients >70 years in the context of the Project of Emilia-Romagna Region in Neuro-Oncology (PERNO), the first Italian prospective observational population-based study in neuro-oncology. For this analysis the criteria for selecting patients enrolled in the PERNO study were: age >70 years; PS 0–3; histologically confirmed GBM; postoperative radiotherapy (RT) after surgery with or without concomitant temozolomide (TMZ) or postsurgical TMZ alone. Between January 2009 and December 2010, 76 GBM elderly patients were identified in the prospective PERNO study. Twenty-three patients did not receive any treatment after surgery, and 53 patients received postsurgical treatments (25 patients received RT alone and 28 patients RT/TMZ). Median survival was 11.1 months (95 % CI 8.8–13.5), adding temozolomide concomitant and adjuvant to radiotherapy it was 11.6 months (95 % CI 8.6–14.6), and 9.3 months (95 % CI 8.1–10.6) in patients treated with RT alone (P = 0.164). However, patients with MGMT methylated treated with RT/TMZ obtained a better survival (17.2 months, 95 % CI 11.5–22.9) (P = 0.042). No difference in terms of survival were observed if patients with MGMT unmethylated tumor received RT alone, or RT/TMZ or, in MGMT methylated tumor, if patients received radiotherapy alone. In elderly patients RT/TMZ represent a widely used approach but it is effective with methylated MGMT tumors only.

Published
2016

23. Erratum to: Survival prediction in high-grade gliomas using CT perfusion imaging [J Neurooncol (2015) 123, 93-102, DOI 10.1007/s11060-015-1766-5]

Author

Yeung T. P. C., Wang Y., He W., Urbini B., Gafa R., Ulazzi L., Yartsev S., Bauman G., Lee T. -Y., Fainardi E., Baruzzi A., Albani F., Calbucci F., D'alessandro R., Michelucci R., Brandes A., Eusebi V., Ceruti S., Tamarozzi R., Emiliani E., Cavallo M., Franceschi E., Tosoni A., Fiorica F., Valentini A., Depenni R., Mucciarini C., Crisi G., Sasso E., Biasini C., Cavanna L., Guidetti D., Marcello N., Pisanello A., Cremonini A. M., Guiducci G., de Pasqua S., Testoni S., Agati R., Ambrosetto G., Bacci A., Baldin E., Baldrati A., Barbieri E., Bartolini S., Bellavista E., Bisulli F., Bonora E., Bunkheila F., Carelli V., Crisci M., Dall'occa P., de Biase D., Ferro S., Franceschi C., Frezza G., Grasso V., Leonardi M., Marucci G., Morandi L., Mostacci B., Palandri G., Pasini E., Pastore Trossello M., Pession A., Poggi R., Riguzzi P., Rinaldi R., Rizzi S., Romeo G., Spagnolli F., Tinuper P., Trocino C., Dall'agata M., Frattarelli M., Gentili G., Giovannini A., Iorio P., Pasquini U., Galletti G., Guidi C., Neri W., Patuelli A., Strumia S., Faedi M., Casmiro M., Gamboni A., Rasi F., Cruciani G., Cenni P., Dazzi C., Guidi A. R., Zumaglini F., Amadori A., Pasini G., Pasquinelli M., Pasquini E., Polselli A., Ravasio A., Viti B., Sintini M., Ariatti A., Bertolini F., Bigliardi G., Carpeggiani P., Cavalleri F., Meletti S., Nichelli P., Pettorelli E., Pinna G., Zunarelli E., Artioli F., Bernardini I., Costa M., Greco G., Guerzoni R., Stucchi C., Iaccarino C., Ragazzi M., Rizzi R., Zuccoli G., Api P., Cartei F., Colella M., Fallica E., Farneti M., Frassoldati A., Granieri E., Latini F., Monetti C., Saletti A., Schivalocchi R., Sarubbo S., Seraceni S., Tola M. R., Zini G., Giorgi C., Montanari E., Cerasti D., Crafa P., Dascola I., Florindo I., Giombelli E., Mazza S., Ramponi V., Servadei F., Silini E. M., Torelli P., Immovilli P., Morelli N., Vanzo C., Nobile C., Yeung T.P.C., Wang Y., He W., Urbini B., Gafa R., Ulazzi L., Yartsev S., Bauman G., Lee T.-Y., Fainardi E., Baruzzi A., Albani F., Calbucci F., D'alessandro R., Michelucci R., Brandes A., Eusebi V., Ceruti S., Tamarozzi R., Emiliani E., Cavallo M., Franceschi E., Tosoni A., Fiorica F., Valentini A., Depenni R., Mucciarini C., Crisi G., Sasso E., Biasini C., Cavanna L., Guidetti D., Marcello N., Pisanello A., Cremonini A.M., Guiducci G., de Pasqua S., Testoni S., Agati R., Ambrosetto G., Bacci A., Baldin E., Baldrati A., Barbieri E., Bartolini S., Bellavista E., Bisulli F., Bonora E., Bunkheila F., Carelli V., Crisci M., Dall'occa P., de Biase D., Ferro S., Franceschi C., Frezza G., Grasso V., Leonardi M., Marucci G., Morandi L., Mostacci B., Palandri G., Pasini E., Pastore Trossello M., Pession A., Poggi R., Riguzzi P., Rinaldi R., Rizzi S., Romeo G., Spagnolli F., Tinuper P., Trocino C., Dall'agata M., Frattarelli M., Gentili G., Giovannini A., Iorio P., Pasquini U., Galletti G., Guidi C., Neri W., Patuelli A., Strumia S., Faedi M., Casmiro M., Gamboni A., Rasi F., Cruciani G., Cenni P., Dazzi C., Guidi A.R., Zumaglini F., Amadori A., Pasini G., Pasquinelli M., Pasquini E., Polselli A., Ravasio A., Viti B., Sintini M., Ariatti A., Bertolini F., Bigliardi G., Carpeggiani P., Cavalleri F., Meletti S., Nichelli P., Pettorelli E., Pinna G., Zunarelli E., Artioli F., Bernardini I., Costa M., Greco G., Guerzoni R., Stucchi C., Iaccarino C., Ragazzi M., Rizzi R., Zuccoli G., Api P., Cartei F., Colella M., Fallica E., Farneti M., Frassoldati A., Granieri E., Latini F., Monetti C., Saletti A., Schivalocchi R., Sarubbo S., Seraceni S., Tola M.R., Zini G., Giorgi C., Montanari E., Cerasti D., Crafa P., Dascola I., Florindo I., Giombelli E., Mazza S., Ramponi V., Servadei F., Silini E.M., Torelli P., Immovilli P., Morelli N., Vanzo C., and Nobile C.

Subjects
PERNO, Gender, Glioblastoma, MGMT, Methylation
Abstract

Background: Clinical and molecular factors are essential to define the prognosis in patients with glioblastoma (GBM). O6-methylguanine-DNA methyltransferase (MGMT) methylation status, age, Karnofsky Performance Status (KPS), and extent of surgical resection are the most relevant prognostic factors. Our investigation of the role of gender in predicting prognosis shows a slight survival advantage for female patients. Methods: We performed a prospective evaluation of the Project of Emilia Romagna on Neuro-Oncology (PERNO) registry to identify prognostic factors in patients with GBM who received standard treatment. Results: A total of 169 patients (99 males [58.6%] and 70 females [41.4%]) were evaluated prospectively. MGMT methylation was evaluable in 140 patients. Among the male patients, 36 were MGMT methylated (25.7%) and 47 were unmethylated (33.6%); among the female patients, 32 were methylated (22.9%) and 25 were unmethylated (17.9%). Survival was longer in the methylated females compared with the methylated males (P = 0.028) but was not significantly different between the unmethylated females and the unmethylated males (P = 0.395). In multivariate analysis, gender and MGMT methylation status considered together (methylated females vs. methylated males; hazard ratio [HR], 0.459; 95% confidence interval [CI], 0.242-0.827; P = 0.017), age (HR, 1.025; 95% CI, 1.002-1.049; P = 0.032), and KPS (HR, 0.965; 95% CI, 0.948-0.982; P < 0.001) were significantly correlated with survival. Conclusions: Survival was consistently longer among MGMT methylated females compared with males. Gender can be considered as a further prognostic factor.

Published
2015

24. The interleukin-1 cluster gene region is associated with multiple sclerosis in an Italian Caucasian population

Author

BORZANI I., TOLA M. R., CANIATTI L., COLLINS A., DE SANTIS G., MAMOLINI E., SCAPOLI C., LUISELLI, DONATA, BORZANI I., TOLA M.R., CANIATTI L., COLLINS A., DE SANTIS G., LUISELLI D., MAMOLINI E., and SCAPOLI C.

Subjects
Adult, Male, Multiple Sclerosis, linkage disequilibrium analysis, Chromosome Mapping, INTERLEUKIN-1 (IL-1) GENE FAMILY, Middle Aged, inferred haplotypes, Polymorphism, Single Nucleotide, White People, Haplotypes, Italy, Case-Control Studies, Multigene Family, Humans, Female, Genetic Predisposition to Disease, IL-1 cluster genes, genetic susceptibility, multiple sclerosis, Interleukin-1
Abstract

BACKGROUND: Polymorphisms of the interleukin-1 (IL-1) gene family have been proposed as potential variants for different diseases including multiple sclerosis (MS). With respect to MS, IL-1 beta (-511 C/T; rs16944), IL-1 beta (+3954 C/T; rs1143634), IL-1 alpha (-889 C/T; rs1800587), IL-1 alpha (+4845 G/T; rs17561), and the variable number of tandem repeats in intron 2 of the IL-1 receptor antagonist (IL-1RN) gene polymorphisms have been studied in different ethnic groups, leading to conflicting results. METHODS: This study investigates the association between IL-1 genes and MS by means of 70 markers spanning the 1.1 Mb region where the IL-1 genes map and exploring both the linkage disequilibrium (LD) and the haplotype structure in a case-control design including 410 subjects (160 patients and 250 controls). RESULTS: From allelic/genotypic tests, significant association was found for several polymorphisms including the IL-1 beta (-511 C/T) variant (P-adjusted = 4.5 x 10(-4)) and some polymorphisms around the IL-1RN gene. The 'block-step' pattern obtained from both the LD map and pairwise analysis identifies four LD regions. Region 1 showed a significant association with MS for the global test (P < 0.0001) and haplotypes containing the IL-1 beta (-511 C/T) variant still demonstrate highly significant association with disease (P-value range: 9.9 x 10(-5) to 0.02). CONCLUSIONS: Our findings support the existence of a causative variant for MS within this candidate region in a representative Italian Caucasian population and, in particular, the role of the IL-1 beta (-511 C/T) variant warrants further investigation.

Published
2010

25. Monitoring the use of disease-modifying drugs in multiple sclerosis

Author

POLUZZI, ELISABETTA, PICCINNI, CARLO, SACRIPANTI, CHIARA, D'ALESSANDRO, ROBERTO, MONTANARO, NICOLA, Tola M. R., International Society of Pharamcoepidemiology, Poluzzi E., Piccinni C., Sacripanti C., Tola M.R., D'Alessandro R., and Montanaro N.

Subjects
DISEASE MODIFYING DRUGS, DATABASE, PHARMACOEPIDEMIOLOGY, MULTIPLE SCLEORIS
Abstract

Background: Current treatment of multiple sclerosis (MS) with disease-modifying drugs (DMDs) includes interferon- (IFN-), glatiramer acetate (GA), and immunosuppressive drugs (e.g., mitoxantrone-MIT, azathioprine-AZA, cyclophosphamide-CY). Knowledge on effectiveness in clinical practice of each DMD, optimal pattern of use (especially, when to start drug therapy) require further investigation. Objectives: To identify criteria for choice of DMDs in MS and to evaluate their comparative effectiveness in clinical practice. Methods: A database of DMDs prescribed to MS pts of an Italian region (4,000,000 inhabitants) provided the following information: patient history, disease characteristics (MS course, disability degree in terms of EDSS, relapses, MRI results), drug therapies (drugs, doses, switches, side effects). Data from May 2006 to December 2007 were collected and the relationship between prescribed drugs and diagnostic parameters was analysed by non-adjusted odds ratio (OR, CI 95%). Results: Data on 934 pts (71% females) were collected. IFN- was prescribed in 73% of cases, followed by GA (12%), by AZA (8%) and by MIT (6%). Other immunosuppressive agents were prescribed only in 1% of cases. IFN-1a represented the most frequent drug choice (67%) in the relapsing remitting pts, whereas in the progressive forms IFN-1b (27%), MIT (25%), and AZA (20%) were significantly preferred to IFN-1a once a week. In pts with high disability (EDSS 3), DMDs with higher frequency of administration (3 times a week, each other day, daily) were significantly preferred to IFN-1a once a week. Conclusions: IFN-1a and GA were preferred in pts with stable and moderate MS, whereas IFN-1b and immunosuppressive agents were especially used in those experienced worsening of the disease. This tool may allow to obtain more solid information on MS therapies and to produce evidence-based recommendations.

Published
2008

26. The Italian Surveillance Program on Natalizumab

Author

Mancardi G. L., Amato M. P., Drago F., Milanese C., Popoli P., Provinciali L., Rossi P., Savettieri G., Tedeschi G., Tola M. R., Vanacore N., Covezzoli A., De Rosa M., Periotto L., Addis A., Martini N., D'ALESSANDRO, ROBERTO, PICCINNI, CARLO, MONTANARO, NICOLA, Società Italiana di Neurologia, Mancardi G.L., Amato M.P., D'Alessandro R., Drago F., Milanese C., Popoli P., Provinciali L., Rossi P., Savettieri G., Tedeschi G., Tola M.R., Vanacore N., Covezzoli A., De Rosa M., Piccinni C., Montanaro N., Periotto L., Addis A., and Martini N.

Subjects
REGISTRY, MULTIPLE SCLEROSIS, NATALIZUMAB
Published
2008

27. Progetto di monitoraggio della prescrizione di farmaci disease-modifying nella sclerosi multipla in Emilia-Romagna

Author

POLUZZI, ELISABETTA, PICCINNI, CARLO, RASCHI, EMANUEL, MONTANARO, NICOLA, Mazzolani M., D’Alessandro R., Tola M. R., Galeotti M., Neri W., Malagù S., Motti L., Poluzzi E., Piccinni C., Raschi E., Mazzolani M., D’Alessandro R., Tola M.R., Galeotti M., Neri W., Malagù S., Motti L., and Montanaro N.

Subjects
IMMUNOMODULANTI, FARMACOEPIDEMIOLOGIA, IMMUNOSOPPRESSORI, SCLEROSI MULTIPLA, REGISTRO
Abstract

Introduzione. La pratica clinica attuale per il trattamento della sclerosi multipla, in termini di terapia con farmaci disease-modifying, prevede il ricorso all’interferone-β o a glatiramer, e in seconda istanza a trattamenti immunosoppressivi (es. azatioprina, mitoxantrone). I primi hanno una sufficiente documentazione in questo ambito, ma presentano l’inconveniente dell’alto costo. I secondi sono di uso ampiamente consolidato per altre situazioni che richiedono immunosoppressione, ma ancora in corso di indagine nella sclerosi multipla. Per identificare elementi aggiuntivi riguardo i criteri alla base della scelta dei farmaci e sull’efficacia comparativa dei vari trattamenti, i Centri per la sclerosi multipla in Emilia- Romagna collaborano tra loro in un progetto di monitoraggio delle terapie farmacologiche prescritte. Metodi. Da maggio 2006 è attivo un database regionale in cui, per ogni paziente in trattamento, vengono inserite dal medico specialista le informazioni relative a: dati anagrafici del paziente, storia della malattia, criteri diagnostici della malattia, trattamento scelto, ricadute, modifica del trattamento, reazioni avverse. I dati pervenuti al settembre 2006, sono stati raccolti in un’analisi descrittiva e analizzati statisticamente. Risultati. Sono stati raccolti i dati relativi a 138 pazienti (75% femmine, 48% con meno di 40 anni). Il decorso relapsing remitting è quello maggiormente presente (77%). La scelta del trattamento è ricaduta nell’85% dei casi sull’interferone-β, nell’8% sul glatiramer e nel 6% sul mitoxantrone; 1 solo soggetto ha ricevuto azatioprina. L’interferone-β1a ha rappresentato la scelta più frequente (74%) nel decorso relapsing remitting, mentre nelle forme progressive è prevalso il ricorso a interferone-β1b (42%), seguito da interferone-β1a e mitoxantrone (21%, ciascuno). L’interferone-β1a è stato usato a tutti i gradi di disabilità, e maggiormente nei casi con bassi punteggi EDSS (46%, EDSS tra 1 e 1,5), mentre il β1b ha trovato maggior impiego nei casi di disabilità più gravi e nei pazienti con un elevato numero di riaccensioni a 12 mesi dalla diagnosi. I pazienti trattati con glatiramer o mitoxantrone presentavano un basso grado di disabilità (in entrambi i casi, EDSS

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results